Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2007;116:434-448
doi: 10.1161/CIRCULATIONAHA.107.702795
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ashrafian, H.
Right arrow Articles by Opie, L. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ashrafian, H.
Right arrow Articles by Opie, L. H.
Related Collections
Right arrow Biochemistry and metabolism
Right arrow Other heart failure
Right arrow Type 2 diabetes
Right arrow Glucose intolerance
Right arrow Heart failure - basic studies

(Circulation. 2007;116:434-448.)
© 2007 American Heart Association, Inc.


Basic Science for Clinicians

Metabolic Mechanisms in Heart Failure

Houman Ashrafian, MA, MRCP; Michael P. Frenneaux, MD, FRCP; Lionel H. Opie, MD, DPhil, FRCP

From the Department of Cardiovascular Medicine (H.A.), University of Oxford, Oxford, and the Department of Cardiovascular Medicine (M.P.F.), University of Birmingham, Edgbaston, UK; and the Hatter Institute for Cardiovascular Research (L.H.O.), Cape Heart Centre and Department of Medicine, University of Cape Town Faculty of Health Sciences, Cape Town, South Africa.

Correspondence to Dr Houman Ashrafian, Department of Cardiovascular Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU, UK. E-mail houman.ashrafian{at}cardiov.ox.ac.uk

Although neurohumoral antagonism has successfully reduced heart failure morbidity and mortality, the residual disability and death rate remains unacceptably high. Though abnormalities of myocardial metabolism are associated with heart failure, recent data suggest that heart failure may itself promote metabolic changes such as insulin resistance, in part through neurohumoral activation. A detrimental self-perpetuating cycle (heart failure -> altered metabolism -> heart failure) that promotes the progression of heart failure may thus be postulated. Accordingly, we review the cellular mechanisms and pathophysiology of altered metabolism and insulin resistance in heart failure. It is hypothesized that the ensuing detrimental myocardial energetic perturbations result from neurohumoral activation, increased adverse free fatty acid metabolism, decreased protective glucose metabolism, and in some cases insulin resistance. The result is depletion of myocardial ATP, phosphocreatine, and creatine kinase with decreased efficiency of mechanical work. On the basis of the mechanisms outlined, appropriate therapies to mitigate aberrant metabolism include intense neurohumoral antagonism, limitation of diuretics, correction of hypokalemia, exercise, and diet. We also discuss more novel mechanistic-based therapies to ameliorate metabolism and insulin resistance in heart failure. For example, metabolic modulators may optimize myocardial substrate utilization to improve cardiac function and exercise performance beyond standard care. The ultimate success of metabolic-based therapy will be manifest by its capacity further to lessen the residual mortality in heart failure.


Key Words: fatty acids • glucose • heart failure • insulin resistance




This article has been cited by other articles:


Home page
Circ Cardiovasc ImagingHome page
T. H. Marwick and M. Schwaiger
The Future of Cardiovascular Imaging in the Diagnosis and Management of Heart Failure, Part 1: Tasks and Tools
Circ Cardiovasc Imaging, July 1, 2008; 1(1): 58 - 69.
[Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
H. Tominaga, H. Katoh, K. Odagiri, Y. Takeuchi, H. Kawashima, M. Saotome, T. Urushida, H. Satoh, and H. Hayashi
Different effects of palmitoyl-L-carnitine and palmitoyl-CoA on mitochondrial function in rat ventricular myocytes
Am J Physiol Heart Circ Physiol, July 1, 2008; 295(1): H105 - H112.
[Abstract] [Full Text] [PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
T. Doenst, H. Bugger, M. Schwarzer, G. Faerber, M. A. Borger, and F. W. Mohr
Three good reasons for heart surgeons to understand cardiac metabolism
Eur. J. Cardiothorac. Surg., May 1, 2008; 33(5): 862 - 871.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
L. H. Opie
Metabolic Management of Acute Myocardial Infarction Comes to the Fore and Extends Beyond Control of Hyperglycemia
Circulation, April 29, 2008; 117(17): 2172 - 2177.
[Full Text] [PDF]


Home page
Circ. Res.Home page
J.-a Kim, Y. Wei, and J. R. Sowers
Role of Mitochondrial Dysfunction in Insulin Resistance
Circ. Res., February 29, 2008; 102(4): 401 - 414.
[Abstract] [Full Text] [PDF]